NO20015065L - Pyrazolobenzodiazepiner som CDK2-inhibitorer - Google Patents

Pyrazolobenzodiazepiner som CDK2-inhibitorer

Info

Publication number
NO20015065L
NO20015065L NO20015065A NO20015065A NO20015065L NO 20015065 L NO20015065 L NO 20015065L NO 20015065 A NO20015065 A NO 20015065A NO 20015065 A NO20015065 A NO 20015065A NO 20015065 L NO20015065 L NO 20015065L
Authority
NO
Norway
Prior art keywords
pyrazolobenzodiazepines
cdk2 inhibitors
cdk2
inhibitors
Prior art date
Application number
NO20015065A
Other languages
English (en)
Other versions
NO20015065D0 (no
Inventor
Qingjie Ding
Jin-Jun Liu
Vincent Stewart Madison
Giacomo Pizzolato
Chung-Chen Wei
Peter Michael Wovkulich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20015065D0 publication Critical patent/NO20015065D0/no
Publication of NO20015065L publication Critical patent/NO20015065L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/22—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20015065A 1999-04-21 2001-10-18 Pyrazolobenzodiazepiner som CDK2-inhibitorer NO20015065L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13037099P 1999-04-21 1999-04-21
PCT/EP2000/003394 WO2000064900A1 (en) 1999-04-21 2000-04-14 Pyrazolobenzodiazepines as cdk2 inhibitors

Publications (2)

Publication Number Publication Date
NO20015065D0 NO20015065D0 (no) 2001-10-18
NO20015065L true NO20015065L (no) 2001-10-18

Family

ID=22444382

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015065A NO20015065L (no) 1999-04-21 2001-10-18 Pyrazolobenzodiazepiner som CDK2-inhibitorer

Country Status (33)

Country Link
US (3) US6440959B1 (no)
EP (1) EP1185529B1 (no)
JP (1) JP3746680B2 (no)
KR (1) KR100481757B1 (no)
CN (2) CN1196703C (no)
AR (1) AR023542A1 (no)
AT (1) ATE279413T1 (no)
AU (1) AU768667B2 (no)
BR (1) BR0009887A (no)
CA (1) CA2367704C (no)
CO (1) CO5170444A1 (no)
CZ (1) CZ20013738A3 (no)
DE (1) DE60014893T2 (no)
DK (1) DK1185529T3 (no)
ES (1) ES2228522T3 (no)
HK (1) HK1046278B (no)
HR (1) HRP20010742A2 (no)
HU (1) HUP0300318A3 (no)
IL (1) IL145764A0 (no)
JO (1) JO2248B1 (no)
MA (1) MA26782A1 (no)
NO (1) NO20015065L (no)
NZ (1) NZ514523A (no)
PE (1) PE20010054A1 (no)
PL (1) PL200933B1 (no)
PT (1) PT1185529E (no)
RU (1) RU2249593C2 (no)
SI (1) SI1185529T1 (no)
TR (1) TR200103016T2 (no)
TW (1) TW585866B (no)
WO (1) WO2000064900A1 (no)
YU (1) YU73101A (no)
ZA (1) ZA200108016B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6520951B1 (en) 1996-09-13 2003-02-18 Scimed Life Systems, Inc. Rapid exchange catheter with detachable hood
CN1596114A (zh) * 2001-11-13 2005-03-16 三维药物公司 取代的1,4－苯并二氮杂䓬类及其在治疗癌症中的应用
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
PL378116A1 (pl) * 2003-02-27 2006-03-06 Abbott Laboratories Heterocykliczne inhibitory kinazy
CN101899049A (zh) * 2004-10-13 2010-12-01 霍夫曼-拉罗奇有限公司 二取代吡唑并苯并二氮杂*类
BRPI0617252A2 (pt) * 2005-10-14 2011-07-19 Hoffmann La Roche regime de administração para benzodiazepina 5-2-clorofenil)-1,2-diidro-7-flìor-8-metóxi-3-metil-pira zolo [3,4-b] [1,4]
BRPI0714886B8 (pt) 2006-07-10 2021-05-25 Paion Uk Ltd sais de benzodiazepina, seus usos e seus processos de preparação, e composição farmacêutica
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
CN104363913B (zh) * 2012-02-02 2018-08-21 申内克斯生物科技公司 Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
CN103288828A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-6H-吲哚并[2,1-c][1,4]-苯并二氮杂卓的方法
CN103288830A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-5H-吡咯并[2,1-c][1,4]-苯并二氮杂卓的方法
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
JP7139323B2 (ja) * 2016-11-01 2022-09-20 エフ．ホフマン－ラ ロシュ アーゲー Ｃｎｓ関連疾患を処置するための１，３－ジヒドロ－１，４－ベンゾジアゼピン－２－チオン
SI3447056T1 (sl) * 2016-12-13 2025-10-30 Transthera Sciences (Nanjing), Inc. Spojina, ki zavira multikinaze in njena kristalna oblika ter njena uporaba
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) * 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
BR112022022477A2 (pt) * 2020-05-08 2022-12-13 Transthera Sciences Nanjing Inc Método para sintetizar composto antitumoral e intermediários do mesmo
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
KR20240006610A (ko) * 2021-05-10 2024-01-15 트랜스테라 사이언시즈 (난징), 인크. 다중-키나제 억제제의 제약 조성물 및 용도
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024030399A2 (en) * 2022-08-02 2024-02-08 Lab1636, Llc Use of a gaba-a pam for reduction of tactile hypersensitivity
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0523846A3 (en) * 1991-06-14 1993-03-17 Merck & Co. Inc. 1,4-benzodiazepines with 5-membered heterocyclic rings
CA2266519C (en) 1996-10-02 2007-01-23 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers

Also Published As

Publication number Publication date
US6440959B1 (en) 2002-08-27
TW585866B (en) 2004-05-01
KR20010112435A (ko) 2001-12-20
AR023542A1 (es) 2002-09-04
CZ20013738A3 (cs) 2002-08-14
CN1603314A (zh) 2005-04-06
ATE279413T1 (de) 2004-10-15
HK1046278A1 (en) 2003-01-03
RU2249593C2 (ru) 2005-04-10
HUP0300318A3 (en) 2004-11-29
NO20015065D0 (no) 2001-10-18
HK1046278B (zh) 2005-08-12
DE60014893T2 (de) 2005-10-13
CO5170444A1 (es) 2002-06-27
ES2228522T3 (es) 2005-04-16
TR200103016T2 (tr) 2002-04-22
YU73101A (sh) 2004-05-12
PT1185529E (pt) 2005-02-28
ZA200108016B (en) 2003-03-26
CN1196703C (zh) 2005-04-13
CA2367704C (en) 2008-06-17
JP3746680B2 (ja) 2006-02-15
PL200933B1 (pl) 2009-02-27
AU4748000A (en) 2000-11-10
WO2000064900A1 (en) 2000-11-02
CN1348455A (zh) 2002-05-08
DK1185529T3 (da) 2005-02-07
HRP20010742A2 (en) 2002-12-31
EP1185529A1 (en) 2002-03-13
US20020183514A1 (en) 2002-12-05
JP2002543081A (ja) 2002-12-17
MA26782A1 (fr) 2004-12-20
US20040198976A1 (en) 2004-10-07
JO2248B1 (en) 2004-10-07
DE60014893D1 (de) 2004-11-18
AU768667B2 (en) 2003-12-18
US6916923B2 (en) 2005-07-12
PE20010054A1 (es) 2001-02-07
CN1279029C (zh) 2006-10-11
PL354405A1 (en) 2004-01-12
US6838558B2 (en) 2005-01-04
SI1185529T1 (en) 2005-02-28
KR100481757B1 (ko) 2005-04-11
BR0009887A (pt) 2002-01-22
CA2367704A1 (en) 2000-11-02
EP1185529B1 (en) 2004-10-13
IL145764A0 (en) 2002-07-25
NZ514523A (en) 2003-11-28
HUP0300318A2 (hu) 2003-06-28

Similar Documents

Publication Publication Date Title
NO20015065D0 (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
NO20021239L (no) Pteridinoner som kinase-inhibitorer
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
PT1181017E (pt) Inibidores de metaloproteases
NO20031006D0 (no) Imidazolo-5-yl-2-anilino-pyrimidiner som midler for inhibering av celleproliferasjon
NO20014642D0 (no) Aminopyrimidiner som sorbitol-dehydrogenase-inhibitorer
ATE295848T1 (de) C-aryl-glucosid-sglt2-inhibitoren
DK1140840T3 (da) omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer
NO20021329D0 (no) Kinaseinhibitorer som terapeutiske midler
EE200100492A (et) Ensüümi IMPDH inhibiitorid
NO20030867L (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
PT1194404E (pt) Inibidores de aspartil-protease
NO20024997D0 (no) 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20014243L (no) Dihetero-substituerte metalloproteaseinhibitorer
NO20021959D0 (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20015247D0 (no) Glysinspaltingssysteminhibitorer som potensielle antipsykotika
NO20014875D0 (no) Promedikamenter for trombin inhibitorer
DE60024101D1 (de) Enzyminhibitoren
PT1339695E (pt) Inibidores da farnesiltransferase
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application